A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate.
- Author:
Min Sik KIM
1
;
Dong Hyun LEE
;
Yu Rim LEE
;
Dong Kyun KIM
;
Suk Hyang BAE
;
Jin Yeon HWANG
;
Kyung A KWON
;
Suee LEE
;
Jin Yeong HAN
;
Ki Uk KIM
;
Sung Hyun KIM
Author Information
- Publication Type:Case Report
- Keywords: Chronic myeloid leukemia; Imatinib mesylate; Subdural hematoma
- MeSH: Adult; Benzamides; Blood Platelets; Female; Headache; Hematoma, Subdural; Hemorrhage; Humans; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesylates; Philadelphia; Piperazines; Pyrimidines; Imatinib Mesylate
- From:Korean Journal of Hematology 2010;45(1):73-75
- CountryRepublic of Korea
- Language:English
- Abstract: Imatinib mesylate (IM) is used to treat a wide range of diseases, including Philadelphia chromosome-positive chronic myeloid leukemia (CML), on account of its high tolerability and low incidence of minor adverse events. Hemorrhage is thought to be a rare complication of IM. Recently, IM has been associated with reduced alpha2-plasmin inhibitor and platelet dysfunction. We report here the case of a 33-year-old female patient with CML who experienced subdural hematoma after an incremental increase in IM dosage due to a loss of complete molecular response. This case indicates that physicians should be alert to this atypical cause of headache in patients taking high-dose IM.
